Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride - an123I-IBZM single photon emission tomography (SPET) study

Psychopharmacology

Volumn 117, Issue 1, 1995, Pages 55-61

  Busatto, G F ^a   Pilowsky, L S ^a   Kerwin, R W ^a   Costa, D C ^b   Ell, P J ^b   Verhoeff, N P L G ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Atypical antipsychotics; D2 dopamine receptors; Remoxipride; Risperidone; Single photon emission tomography

Indexed keywords

3 IODO 2 HYDROXY 6 METHOXY N ((1 ETHYL 2 PYRROLIDINYL)METHYL)BENZAMIDE; 3-IODO-2-HYDROXY-6-METHOXY-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)BENZAMIDE; BENZAMIDE DERIVATIVE; DIAGNOSTIC AGENT; DOPAMINE 2 RECEPTOR; ISOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PIPERIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; RADIOACTIVE IODINE; REMOXIPRIDE; RISPERIDONE; AMITRIPTYLINE; CARBAMAZEPINE; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; IODINE 123; LITHIUM CARBONATE; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE;

ADULT; ARTICLE; BASAL GANGLION; BRAIN CORTEX; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HISTOLOGY; HUMAN; IMAGE PROCESSING; MALE; METABOLISM; NEOSTRIATUM; PSYCHOSIS; RATING SCALE; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR OCCUPANCY; SCHIZOIDISM;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA; BENZAMIDES; CEREBRAL CORTEX; FEMALE; HUMAN; IMAGE PROCESSING, COMPUTER-ASSISTED; IODINE RADIOISOTOPES; ISOXAZOLES; MALE; MIDDLE AGE; NEOSTRIATUM; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; PYRROLIDINES; RECEPTORS, DOPAMINE D2; REMOXIPRIDE; RISPERIDONE; SCHIZOPHRENIA; SUPPORT, NON-U.S. GOV'T; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0028985379     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/BF02245098     Document Type: Article

References (31)

1. A rating scale for drug-induced akathisia
2. Risperidone: clinical safety and efficacy in schizophrenia
3. 2 receptor imaging with SPECT: studies in different neuropsychiatric disorders
4. 2 receptor occupancy in vivo and response to the new antipsychotic risperidone: a case study
5. 2 sites
6. Distribution of remoxipride to the human brain and central D2- dopamine receptor binding examined in vivo by PET
7. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects
8. New antipsychotics: classification, efficacy and adverse effects
9. The history of clozapine
10. Clinical treatment of schizophrenia
11. 2 antagonistic properties
12. Atypical antipsychotics: a history of the concept and recent research
13. Clinical profile of remoxipride — a combined analysis of a comparative double-blind multicentre trial programme
14. 2 receptors
15. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone
16. 76Br bromospiperone in untreated schizophrenic patients
17. New drugs for the treatment of schizophrenia
18. i values
19. 3 receptors
20. 2 dopamine receptor occupancy in the living human brain
21. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain
22. Neuropharmacological and behavioral properties of remoxipride in the rat
23. The brief psychiatric rating scale
24. Relationship of neuroleptic drug effects at brain dopamine, serotonin, alfa-adrenergic, and histamine receptors to clinical potency
25. 123I-IBZM single photon emission computerised tomography study
26. 123I-IBZM SPET (single photon emission tomography) study
27. 2 dopamine receptor blockade hypothesis of schizophrenia
28. Antipsychotic drug doses and neuroleptic/dopamine receptors
29. A rating scale for extrapyramidal side effects